|
1
|
Habermacher GM, Chason JT and Schaeffer
AJ: Prostatitis/chronic pelvic pain syndrome. Annu Rev Med.
57:195–206. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nickel JC and Shoskes DA: Phenotypic
approach to the management of the chronic prostatitis/chronic
pelvic pain syndrome. BJU Int. 106:1252–1263. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shoskes DA, Nickel JC, Rackley RR and
Pontari MA: Clinical phenotyping in chronic prostatitis/chronic
pelvic pain syndrome and interstitial cystitis: a management
strategy for urologic chronic pelvic pain syndromes. Prostate
Cancer Prostatic Dis. 12:177–183. 2009. View Article : Google Scholar
|
|
4
|
Nickel JC, Shoskes DA and Wagenlehner FM:
Management of chronic prostatitis/chronic pelvic pain syndrome
(CP/CPPS): the studies, the evidence and the impact. World J Urol.
31:747–753. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nickel JC, Downey J, Ardern D, Clark J and
Nickel K: Failure of a monotherapy strategy for difficult chronic
prostatitis/chronic pelvic pain syndrome. J Urol. 172:551–554.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shoskes DA, Hakim L, Ghoniem G and Jackson
CL: Long-term results of multimodal therapy for chronic
prostatitis/chronic pelvic pain syndrome. J Urol. 169:1406–1410.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shoskes DA, Nickel JC and Kattan MW:
Phenotypically directed multimodal therapy for chronic
prostatitis/chronic pelvic pain syndrome: a prospective study using
UPOINT. Urology. 75:1249–1253. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Magri V, Wagenlehner F, Perletti G,
Schneider S, Marras E, Naber KG and Weidner W: Use of the UPOINT
chronic prostatitis/chronic pelvic pain syndrome classification in
European patient cohorts: sexual function domain improves
correlations. J Urol. 184:2339–2345. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Samplaski MK, Li J and Shoskes DA:
Clustering of UPOINT domains and subdomains in men with chronic
prostatitis/chronic pelvic pain syndrome and contribution to
symptom severity. J Urol. 188:1788–1793. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhao Z, Zhang J, He J and Zeng G: Clinical
utility of the UPOINT phenotype system in Chinese males with
chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a
prospective study. PLoS One. 8:e520442013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shoskes DA and Nickel JC: Classification
and treatment of men with chronic prostatitis/chronic pelvic pain
syndrome using the UPOINT system. World J Urol. 31:755–760. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Davis SN, Binik YM, Amsel R and Carrier S:
Is a sexual dysfunction domain important for quality of life in men
with urological chronic pelvic pain syndrome? Signs ‘UPOINT’ to
yes. J Urol. 189:146–151. 2013. View Article : Google Scholar
|
|
13
|
Giubilei G, Mondaini N, Crisci A, Raugei
A, Lombardi G, Travaglini F, et al: The Italian version of the
National Institutes of Health Chronic Prostatitis Symptom Index.
Eur Urol. 47:805–811. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Propert KJ, Litwin MS, Wang Y, Alexander
RB, Calhoun E, Nickel JC, et al: Responsiveness of the National
Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI).
Qual Life Res. 15:299–305. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rosen RC, Cappelleri JC and Gendrano N:
The International Index of Erectile Function (IIEF): a
state-of-the-science review. Int J Impot Res. 14:226–244. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Magri V, Montanari E, Škerk V, Markotić A,
Marras E, Restelli A, Naber KG and Perletti G:
Fluoroquinolone-macrolide combination therapy for chronic bacterial
prostatitis: retrospective analysis of pathogen eradication rates,
inflammatory findings and sexual dysfunction. Asian J Androl.
13:819–827. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Morgia G, Cimino S, Favilla V, Russo GI,
Squadrito F, Mucciardi G, et al: Effects of Serenoa repens,
selenium and lycopene (Profluss®) on chronic
inflammation associated with benign prostatic hyperplasia: results
of ‘FLOG’ (Flogosis and Profluss in Prostatic and Genital Disease),
a multicentre Italian study. Int Braz J Urol. 39:214–221.
2013.PubMed/NCBI
|
|
18
|
Morgia G, Mucciardi G, Galì A, Madonia M,
Marchese F, Di Benedetto A, et al: Treatment of chronic
prostatitis/chronic pelvic pain syndrome category IIIa with Serenoa
repens plus selenium and lycopene (Profluss) versus S. repens
alone: an Italian randomized multicenter-controlled study. Urol
Int. 84:400–406. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vickers AJ: Parametric versus
non-parametric statistics in the analysis of randomized trials with
non-normally distributed data. BMC Med Res Methodol. 5:352005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Krieger JN, Nyberg L Jr and Nickel JC: NIH
consensus definition and classification of prostatitis. JAMA.
282:236–237. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wagenlehner FM, van Till JW, Magri V,
Perletti G, Houbiers JG, Weidner W and Nickel JC: National
Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI)
symptom evaluation in multinational cohorts of patients with
chronic prostatitis/chronic pelvic pain syndrome. Eur Urol.
63:953–959. 2013. View Article : Google Scholar
|
|
22
|
Wagenlehner FM, Weidner W and Naber KG:
Therapy for prostatitis, with emphasis on bacterial prostatitis.
Expert Opin Pharmacother. 8:1667–1674. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wagenlehner FM, Ballarini S and Naber KG:
Immunostimulation in chronic prostatitis/chronic pelvic pain
syndrome (CP/CPPS): a one-year prospective, double-blind,
placebo-controlled study. World J Urol. 32:1595–1603. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tran CN and Shoskes DA: Sexual dysfunction
in chronic prostatitis/chronic pelvic pain syndrome. World J Urol.
31:741–746. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schaeffer AJ, Knauss JS, Landis JR,
Propert KJ, Alexander RB, Litwin MS, et al: Leukocyte and bacterial
counts do not correlate with severity of symptoms in men with
chronic prostatitis: the National Institutes of Health Chronic
Prostatitis Cohort Study. J Urol. 168:1048–1053. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nickel JC, Alexander RB, Schaeffer AJ,
Landis JR, Knauss JS, Propert KJ, et al: Leukocytes and bacteria in
men with chronic prostatitis/chronic pelvic pain syndrome compared
to asymptomatic controls. J Urol. 170:818–822. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sung YH, Jung JH, Ryang SH, Kim SJ and Kim
KJ: Clinical significance of national institutes of health
classification in patients with chronic prostatitis/chronic pelvic
pain syndrome. Korean J Urol. 55:276–280. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Parnham MJ, Haber VE,
Giamarellos-Bourboulis EJ, Perletti G, Verleden GM and Vos R:
Azithromycin: Mechanisms of action and their relevance for clinical
applications. Pharmacol Ther. 143:225–245. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Perletti G, Skerk V, Magri V, Markotic A,
Mazzoli S, Parnham MJ, Wagenlehner FM and Naber KG: Macrolides for
the treatment of chronic bacterial prostatitis: an effective
application of their unique pharmacokinetic and pharmacodynamic
profile. Mol Med Rep. 4:1035–1044. 2011.PubMed/NCBI
|
